Florence Roufosse Selected Research

Hypereosinophilic Syndrome (Loeffler Endocarditis)

1/2022	An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
1/2022	From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
1/2022	Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
12/2021	Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
2/2021	Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.
12/2020	Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
1/2020	Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.
1/2015	Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy.
10/2010	Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
12/2009	Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Florence Roufosse Research Topics

Disease

14	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022 - 09/2002
10	Eosinophilia 01/2022 - 09/2002
3	Churg-Strauss Syndrome (Allergic Angiitis) 01/2022 - 01/2010
3	Asthma (Bronchial Asthma) 01/2022 - 01/2018
1	Rhinosinusitis 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2020
1	Rare Diseases (Rare Disease) 10/2019
1	Splenomegaly 01/2016
1	Lymphocytosis 01/2016
1	Lymphopenia (Lymphocytopenia) 01/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Chronic Disease (Chronic Diseases) 10/2009
1	Lymphoma (Lymphomas) 10/2009
1	T-Cell Lymphoma (Lymphoma, T Cell) 09/2008
1	Neoplasms (Cancer) 09/2008
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 09/2008

Drug/Important Bio-Agent (IBA)

9	mepolizumabIBA 01/2022 - 01/2010
6	Interleukin-5 (Interleukin 5)IBA 01/2022 - 06/2005
3	Biological ProductsIBA 01/2022 - 01/2003
3	AntibodiesIBA 01/2020 - 09/2008
3	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019 - 04/2006
2	benralizumabIBA 01/2022 - 02/2021
2	Imatinib Mesylate (Gleevec)FDA Link 01/2016 - 04/2006
2	CytokinesIBA 04/2012 - 10/2005
1	anti-IgE antibodiesIBA 01/2022
1	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 01/2022
1	reslizumabIBA 01/2022
1	dupilumabIBA 01/2022
1	Omalizumab (Xolair)FDA Link 01/2022
1	Alemtuzumab (Campath)FDA Link 01/2022
1	Reducing AgentsIBA 01/2022
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	Growth Factor ReceptorsIBA 12/2021
1	Monoclonal AntibodiesIBA 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	Methylprednisolone FDA LinkGeneric 01/2016
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2016
1	GlucocorticoidsIBA 01/2016
1	fludarabineIBA 01/2015
1	Indicators and Reagents (Reagents)IBA 09/2012
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2010
1	MicroRNAs (MicroRNA)IBA 10/2009
1	ParaffinIBA 09/2008
1	ChemokinesIBA 09/2008
1	Chemokine CCL5IBA 09/2008
1	N 30IBA 09/2008
1	T-Cell Antigen Receptor-CD3 ComplexIBA 10/2005
1	gamma chain CD3 antigenIBA 10/2005
1	Chemokine CCL17IBA 09/2002

Therapy/Procedure

4	Therapeutics 12/2020 - 04/2006
1	Biological Therapy 10/2019